Wim Geomaere Biopharmaceutical firm Bone Therapeutics, which develops cell therapy products to treat bone diseases, has named Wim Geomaere chief financial officer – effective 17 September 2013. Prior
Financings In the third quarter of 2011, biopharma start-ups raised $299 million – $48 million more than last quarter, with more than half of the funding going to Series A rounds. ( See Exhibit 1. )Me
Amakem, the Belgian ophthalmology start-up spun out from Devgen early in 2010, has secured an €18 million series A financing to take its lead drug candidate to clinical proof of concept. The firm is w
Biocartis, a developer of molecular diagnostic solutions, has appointed Hilde Windels chief financial officer, as well as managing director of Biocartis NV (a wholly owned subsidiary of Biocartis SA)